EWTX net incomeQ2 2026-$57.33M
EWTX net income was -$57.33M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$36.12M a year earlier. For the full fiscal 2025 it was -$167.79M, compared with -$133.81M in fiscal 2024.
Edgewise Therapeutics Inc. (EWTX) financials
For the twelve months ended Jun 30, 2026, Edgewise Therapeutics Inc. reported -$197.22M of net income.
- Net income, TTM
- -$197.22M
- Free cash flow, TTM
- -$158.83M
- EPS, diluted, TTM
- -$1.85
- Cash
- $72.32M
- Market cap
- $4.08B
FY2020FY2025
FY2020FY2025
EWTX revenue and earnings growth
EWTX EPSQ2 2026-$0.53
EWTX diluted EPS was -$0.53 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.34 a year earlier. For the full fiscal 2025 it was -$1.63, compared with -$1.45 in fiscal 2024.
EWTX free cash flowQ2 2026-$42.50M
EWTX free cash flow was -$42.50M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$32.63M a year earlier. For the full fiscal 2025 it was -$144.07M, compared with -$110.34M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Research and development | $151.39M | $126.97M | $90.91M | $54.03M | $32.19M | $14.98M |
| Selling, general and admin | $40.02M | $31.87M | $23.45M | $17.63M | $11.03M | $2.21M |
| Operating income | -$191.41M | -$158.83M | -$114.36M | -$71.66M | -$43.22M | -$17.19M |
| Pre-tax income | -$167.80M | -$133.80M | -$100.20M | - | - | - |
| Income tax | $4.0K | $3.0K | $4.0K | $0 | $0 | - |
| Net income | -$167.79M | -$133.81M | -$100.16M | -$67.64M | -$42.81M | -$17.12M |
| EPS, basic | -$1.63 | -$1.45 | -$1.57 | -$1.26 | -$1.14 | -$23.17 |
| EPS, diluted | -$1.63 | -$1.45 | -$1.57 | -$1.26 | -$1.14 | -$23.17 |
| Diluted shares | 102.9M | 92.4M | 63.7M | 53.6M | 37.5M | 739,004 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $61.15M | $41.67M | $86.10M | $21.99M | $15.57M | $104.92M |
| Current assets | $543.38M | $475.48M | $327.00M | $357.00M | $283.77M | $129.65M |
| Total assets | $552.60M | $486.82M | $340.04M | $367.10M | $285.23M | $131.14M |
| Current liabilities | $27.37M | $23.86M | $16.77M | $16.59M | $10.52M | $4.34M |
| Total liabilities | $30.35M | $27.60M | $21.20M | $20.39M | $10.85M | $4.34M |
| Shareholders' equity | $522.26M | $459.22M | $318.83M | $346.72M | $274.38M | -$33.42M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$143.82M | -$109.03M | -$91.95M | -$52.63M | -$33.51M | -$14.63M |
| Capital expenditures | $256.0K | $1.31M | $5.75M | $5.55M | $668.0K | $203.0K |
| Free cash flow | -$144.07M | -$110.34M | -$97.69M | -$58.18M | -$34.17M | -$14.84M |
| Investing cash flow | -$32.79M | -$184.66M | $102.89M | -$70.58M | -$242.23M | -$24.38M |
| Financing cash flow | $196.09M | $249.25M | $53.17M | $129.64M | $186.38M | $120.28M |
| Stock-based compensation | $34.75M | $24.71M | $17.56M | $10.92M | $4.40M | $354.0K |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $47.55M | $42.65M | $43.59M | $37.48M | $33.56M | $36.76M | $36.37M | $32.22M | $30.68M | $27.69M | $27.68M | $23.79M |
| Selling, general and admin | $14.39M | $11.46M | $12.38M | $9.38M | $9.05M | $9.20M | $9.17M | $8.21M | $7.43M | $7.06M | $6.18M | $5.67M |
| Operating income | -$61.94M | -$54.12M | -$55.98M | -$46.86M | -$42.61M | -$45.96M | -$45.54M | -$40.43M | -$38.11M | -$34.75M | -$33.86M | -$29.45M |
| Net income | -$57.33M | -$49.01M | -$50.22M | -$40.67M | -$36.12M | -$40.80M | -$39.66M | -$34.13M | -$31.50M | -$28.52M | -$30.14M | -$25.71M |
| EPS, basic | -$0.53 | -$0.46 | -$0.47 | -$0.39 | -$0.34 | -$0.43 | -$0.42 | -$0.36 | -$0.34 | -$0.33 | -$0.46 | -$0.41 |
| EPS, diluted | -$0.53 | -$0.46 | -$0.47 | -$0.39 | -$0.34 | -$0.43 | -$0.42 | -$0.36 | -$0.34 | -$0.33 | -$0.46 | -$0.41 |
| Diluted shares | 107.7M | 107.1M | - | 105.5M | 104.9M | 95.1M | - | 93.8M | 93.5M | 87.6M | - | 63.5M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $72.32M | $33.21M | $61.15M | $46.00M | $43.40M | $49.92M | $41.67M | $44.81M | $43.48M | $30.26M | $86.10M | $32.96M |
| Current assets | $471.52M | $509.79M | $543.38M | $573.90M | $603.25M | $443.18M | $475.48M | $499.44M | $519.44M | $541.43M | $327.00M | $297.92M |
| Total assets | $479.69M | $518.52M | $552.60M | $583.47M | $613.33M | $454.39M | $486.82M | $511.28M | $531.65M | $553.81M | $340.04M | $311.36M |
| Current liabilities | $29.04M | $22.54M | $27.37M | $21.65M | $20.90M | $21.11M | $23.86M | $18.96M | $17.18M | $14.60M | $16.77M | $16.34M |
| Total liabilities | $31.61M | $25.32M | $30.35M | $24.82M | $24.26M | $24.67M | $27.60M | $22.41M | $21.17M | $18.86M | $21.20M | $20.94M |
| Shareholders' equity | $448.08M | $493.20M | $522.26M | $558.65M | $589.07M | $429.72M | $459.22M | $488.88M | $510.47M | $534.94M | $318.83M | $290.43M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$42.47M | -$42.54M | -$38.59M | -$34.78M | -$32.58M | -$37.87M | -$26.96M | -$27.37M | -$26.10M | -$28.60M | -$26.83M | -$22.06M |
| Capital expenditures | $32.0K | $260.0K | $73.0K | $89.0K | $50.0K | $44.0K | $274.0K | $520.0K | $221.0K | $297.0K | $161.0K | $457.0K |
| Free cash flow | -$42.50M | -$42.80M | -$38.66M | -$34.87M | -$32.63M | -$37.91M | -$27.23M | -$27.89M | -$26.32M | -$28.89M | -$26.99M | -$22.52M |
| Investing cash flow | $78.49M | $2.43M | $49.76M | $35.72M | -$162.17M | $43.90M | $20.92M | $25.36M | $37.37M | -$268.31M | $26.98M | $23.42M |
| Financing cash flow | $3.09M | $12.17M | $3.98M | $1.66M | $188.23M | $2.22M | $2.90M | $3.33M | $1.95M | $241.07M | $52.99M | -$211.0K |
| Stock-based compensation | $9.36M | $8.71M | $9.88M | $8.09M | $7.73M | $9.06M | $7.74M | $6.88M | $5.22M | $4.87M | $5.15M | $4.56M |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 16.24 | 22.61 | 19.85 | 26.51 | 28.87 | 20.99 | 19.93 | 26.35 | 30.24 | 37.08 | 19.50 | 18.23 |
Source: XBRL data Edgewise Therapeutics Inc. files with the SEC, latest filing dated Aug 6, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
EWTX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| EWTX | - | - | -$197.22M | - | $4.08B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $665.19B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $521.00B |
| MRK | $66.57B | +4.6% | $3.17B | 4.8% | $370.96B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $314.81B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.10B |
| ABT | $45.13B | +6.6% | $6.28B | 13.9% | $199.88B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $186.77B |
EWTX FAQ
6 questionsIs EWTX profitable?
No. Edgewise Therapeutics Inc. reported a net loss of $197.22M for the twelve months ended Jun 30, 2026.How much cash and debt does EWTX have?
Edgewise Therapeutics Inc. reported $72.32M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is EWTX free cash flow?
Edgewise Therapeutics Inc. generated -$158.83M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$158.38M less capital expenditures.What is EWTX earnings per share?
Diluted earnings per share were -$1.85 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did EWTX last report financial results?
The latest statements here come from Edgewise Therapeutics Inc.'s 10-Q filed on Aug 6, 2026, covering the period ended Jun 30, 2026.Where does this EWTX financial data come from?
Quantisnow builds these statements from the structured XBRL data Edgewise Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.